By Denny Jacob
Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib.
Shares were trading around $4.33. The stock is down 38% on the year.
The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile.
Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus.
The company said it's on track to initiate a Phase 2 trial before the end of the year.
Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 09, 2025 08:35 ET (12:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。